Skip to main content

Advertisement

Table 1 CAR T cell therapy in lymphoma

From: Novel and emerging therapies for B cell lymphoma

CAR T cell productAxicabtagene ciloleucel (Yescarta)Tisagenlecleucel (Kymriah)Lisocabtagene maraleucel
Costimulation domainCD-284-1BB4-1BB
VectorRetrovirusLentivirusLentivirus
Conditioning regimenFludarabine, cyclophosphamideFludarabine, cyclophosphamide, or bendamustineFludarabine, cyclophosphamide
Pivotal trialZUMA-1 (N = 108)JULIET (N = 111)TRANSCEND-NHL-001 (N = 102)
HistologyDLBCL, tFL, PMBCLDLBCL, tFLDLBCL,PMBCL, FL, tFL
CAR T cell dosage2 × 106 cells/kg3 × 108 cells/kg1 × 108 cells/kg
ORR83%52%75%
CR58%40%55%
Median DOR (months)11.1 (95% CI, 4.2—NE)NR (95% CI, 10—NR)NA
Overall survival24-month survival, 50.5% (95% CI 40.2–59.7)11.7 months (95% CI, 6.6—NE)NA
Any grade CRS/NT93%/64 %58%/21%37%/25 %
Grade ≥ 3 CRS13%22%1%
Grade ≥ 3 NT28%12%15%
Tocilizumab/steroid usage43%/27%15%/10%17%/21%
Grade 5 AEs4%NoneNone
Reference[11, 13][9, 14][12, 15]
  1. Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, CRS cytokine release syndrome, NT neurotoxicity, DOR duration of response, CAR chimeric antigen receptor, AE adverse event, DLBCL diffuse large B cell lymphoma, tFL transformed follicular lymphoma, FL follicular lymphoma, PMBCL primary mediastinal B cell lymphoma, NE not estimated, NR not reached, NA data unavailable